F.D.A. Rejects Closely Watched Lung Cancer Drug From China

3 hours ago 3

You person a preview presumption of this nonfiction portion we are checking your access. When we person confirmed access, the afloat nonfiction contented volition load.

The treatment, called ivonescimab, has go a awesome of China’s emergence successful cause development.

An X-ray representation  of lungs, with definite  parts appearing discolored.
This X-ray shows signifier 1 cancer. Summit Therapeutics of Florida had been seeking to bring to the U.S. marketplace a cause for lung cancer, called ivonescimab, that was invented successful China.Credit...James Cavallini/Universal Images Group, via Getty Images

Rebecca Robbins

Nov. 15, 2026, 3:33 p.m. ET

The Food and Drug Administration rejected a first-of-its-kind crab cause that was invented successful China, a setback for a medicine that had go a awesome of China’s ascendance arsenic a powerhouse successful cause development.

Summit Therapeutics, the Florida institution that has been seeking to bring the cause to the American market, disclosed the agency’s determination successful a news merchandise connected Sunday. Summit bought the U.S. rights to the cause from Akeso Biopharma, a Chinese drugmaker that invented the cause successful its laboratories and sells it successful China.

Summit had been seeking support lone for definite patients with precocious lung cancer. But the cause had raised precocious hopes due to the fact that it is being tested successful galore much cancers, including tumors of the colon, bladder and breast.

Summit said connected Sunday that the F.D.A. told the institution it had rejected the cause due to the fact that it had not shown a statistically important payment successful prolonging patients’ lives successful the planetary objective proceedings that was the ground of Summit’s application.

Summit had been seeking F.D.A. support based connected the results of a study the institution conducted successful the United States, Canada, Europe and Asia that enrolled patients who had already tried a targeted treatment. The proceedings compared patients who received ivonescimab and chemotherapy with those whose lone attraction was chemotherapy. In that study, the cause was palmy successful delaying the cancer’s progression.

Summit has argued that the nonaccomplishment to widen patients’ lives simply reflected dilatory enrollment successful the study. Hoping to bolster its case, the institution had sent the F.D.A. analyses that were not specified successful the archetypal probe program of patients’ longer-time outcomes, but those were not capable to transportation regulators.


Thank you for your patience portion we verify access. If you are successful Reader mode delight exit and log into your Times account, or subscribe for each of The Times.


Thank you for your patience portion we verify access.

Already a subscriber? Log in.

Want each of The Times? Subscribe.

Read Entire Article